Stifel Nicolaus assumed coverage on shares of Genocea Biosciences (NASDAQ:GNCA) in a research report released on Monday, BenzingaRatingsTable reports. The firm issued a buy rating on the biotechnology company’s stock.
Several other brokerages have also recently weighed in on GNCA. ValuEngine cut Zumiez from a hold rating to a sell rating in a report on Tuesday, July 2nd. Zacks Investment Research upgraded HB Fuller from a sell rating to a hold rating in a report on Wednesday, July 3rd. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. Genocea Biosciences presently has a consensus rating of Buy and an average target price of $5.13.
GNCA opened at $3.66 on Monday. The company has a debt-to-equity ratio of 1.45, a current ratio of 2.51 and a quick ratio of 2.51. The stock has a market cap of $94.76 million, a P/E ratio of -0.99 and a beta of 2.41. The business’s fifty day moving average price is $4.60. Genocea Biosciences has a 52 week low of $2.24 and a 52 week high of $11.28.
In other Genocea Biosciences news, major shareholder Peter W. Sonsini bought 2,857,142 shares of the firm’s stock in a transaction dated Monday, June 24th. The stock was acquired at an average price of $3.50 per share, for a total transaction of $9,999,997.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 2.33% of the company’s stock.
An institutional investor recently raised its position in Genocea Biosciences stock. Fosun International Ltd lifted its holdings in shares of Genocea Biosciences Inc (NASDAQ:GNCA) by 41.5% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 571,028 shares of the biotechnology company’s stock after purchasing an additional 167,350 shares during the period. Fosun International Ltd owned about 0.51% of Genocea Biosciences worth $345,000 as of its most recent SEC filing.
About Genocea Biosciences
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses.
Featured Story: What are catch-up contributions?
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.